RT Journal Article
SR Electronic
T1 Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 603
OP 608
DO 10.1136/jclinpath-2019-205830
VO 72
IS 9
A1 Nobuyasu Kurihara
A1 Kazuhiro Imai
A1 Hiroshi Nanjo
A1 Ryuta Nakamura
A1 Yuki Wakamatsu
A1 Koji Akagami
A1 Kaori Terata
A1 Akiyuki Wakita
A1 Yusuke Sato
A1 Satoru Motoyama
A1 Yoichi Akagami
A1 Yoshihiro Minamiya
YR 2019
UL http://jcp.bmj.com/content/72/9/603.abstract
AB Aims Human epidermal growth factor receptor 2 (HER2)-targeted agents are effective against HER2-positive breast cancers. However, their lack of survival benefit in HER2-negative patients as well as their toxic effects and high cost highlight the need for accurate assessment of HER2 status. Our aim was to evaluate the clinical utility of a reagent-saving in situ hybridisation (Saving ISH) that facilitates hybridisation and saves HER2/chromosome enumeration probe by taking advantage of the non-contact mixing effect of an alternating current (AC) electric field.Methods With a new device, we apply a high-voltage, low-frequency AC electric field to the tissue sections, which mixes the probe within microdroplets as the voltage is switched on and off. Specimens (n=113) from patients with breast cancers identified immunohistochemically as HER2 0/1(+), (2+) or (3+) were used. The specimens were all tested using conventional dual ISH (DISH), DISH with an automated slide stainer (ASS) and Saving ISH (1:1–1:3 dilution).Results The Saving ISH with 1:2 probe dilution produced stable results with less non-specific staining while using smaller amounts of probe. The accuracy of HER2 status with Saving ISH was equal to standard. We found 96.4% agreement between DISH using ASS and Saving ISH (kappa coefficient=0.912).Conclusions These results suggest reagent-saving HER2 ISH could be used as a clinical tool for accurate and stable HER2 assessment, even when reagent concentrations vary.